Clinical Trials at University of Iowa Hospitals and Clinics
As of June 2026, 67 paid clinical trials are recruiting at University of Iowa Hospitals and Clinics, located at 200 HAWKINS DR, DEPARTMENT OF SURGERY, 1529 JCP, IOWA CITY, IA 52242-1009, phone (319) 467-5302 in Iowa City, Iowa. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Multiple Myeloma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
67 clinical trials at University of Iowa Hospitals and Clinics
·Clear filters·↓ Download CSVNV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Concomitant LAAC/AF Ablation (Watchman FLX Pro)
Onyx™ Liquid Embolic IDE Clinical Study
Home-Based Monitoring in Parkinson's Disease
Early Angiotensin II in the Emergency Department
Post-Filter Hematocrit
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
MED-EL Remote Care Multi-Center Feasibility Study
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
Behavioral Economic & Staffing Strategies in the ICU
Paced Heart Rate Acceleration for Cardiac Conditioning
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Preventing Injured Knees From osteoArthritis: Severity Outcomes
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Acceptance and Commitment Therapy for Patients Undergoing Coronary Artery Bypass Graft Surgery
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Test-retest Evaluation of [18F]F-AraG PET
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Lurbinectedin in FET-Fused Tumors
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Limited-duration Teclistamab
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
About research studies in Iowa City
Iowa City has approximately 591 recruiting research studies across a wide range of therapeutic areas. Iowa hosts a diverse network of universities, academic medical centers, and community hospitals that run clinical trials across oncology, cardiology, neurology, and many other therapeutic areas.
Common conditions studied in Iowa City
- Acute Myeloid Leukemia (11 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Breast Cancer (11 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Multiple Myeloma (8 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Hearing Loss, Sensorineural (6 active studies). Recruiting Hearing Loss, Sensorineural studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Bladder Cancer (5 active studies). Recruiting Bladder Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Duchenne Muscular Dystrophy (5 active studies). Recruiting Duchenne Muscular Dystrophy studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Iowa City
- University of Iowa
- National Cancer Institute (NCI)
- Children's Oncology Group
- AstraZeneca
- Anna Stanhewicz, PhD
Local regulations and guidelines
Clinical trials in Iowa are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Iowa research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Iowa City. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Iowa City
Hipa.ai aggregates every recruiting study in Iowa City from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Iowa City?
There are approximately 591 recruiting clinical trials in Iowa City, Iowa listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Iowa City pay participants?
Most recruiting trials in Iowa City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Iowa City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Iowa City?
The most common conditions under active study in Iowa City include Acute Myeloid Leukemia (11), Breast Cancer (11), Multiple Myeloma (8), Hearing Loss, Sensorineural (6), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Iowa City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Iowa City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Iowa City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Iowa City?
Recruiting research sites in Iowa City include University of Iowa, University of Iowa/Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Iowa City right now?
The largest active categories in Iowa City are Cancer & tumors (184), Neurology & pain (37), Cardiovascular (30). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Iowa Hospitals and Clinics?
University of Iowa Hospitals and Clinics is located at 200 HAWKINS DR, DEPARTMENT OF SURGERY, 1529 JCP, IOWA CITY, IA 52242-1009. Use the Google Maps link in the intro above to get directions.
How do I contact University of Iowa Hospitals and Clinics?
You can reach University of Iowa Hospitals and Clinics by phone at (319) 467-5302. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.